Business Information
The group's principal activity is the discovery, development and commercialization of products designed to treat asthma and critical care diseases linked to body's inflammatory response. The group currently has one fda-approved product, zyflo (R), a tablet formulation for asthma. In addition, the group has three programs directed at developing products to regulate the excessive inflammatory response that can damage vital internal organs and, in the most severe cases, result in multiple organ failure and death.
|
|
Name |
Title
|
Email
|
| Trevor Phillips | COO, Sr. VP - Operations | Available | | Tucker Kelly | CFO, Sr. VP - Finance, Corporate Development | Available | | Linda Lennox | VP - Investor, Media Relations | Available | | Roberta Tucker | Sr. VP - Regulatory Affairs | Available | | Roger Heerman | VP - Sales, Marketing | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 13,078 | (48,782) | | 2005 | 6,224 | (47,090) | | 2004 | 4,436 | (31,094)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
